A Registry for Patients by the Pulmonary Fibrosis Foundation

Overview

About this study

The purpose of the Pulmonary Fibrosis Foundation Patient Registry is to collect data on well-characterized patients with interstitial lung disease, especially idiopathic pulmonary fibrosis, for participation in retrospective and prospective research.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • 18 years or older
  • Understand and sign the informed consent document
  • ILD diagnosis made and confirmed at a participating Registry center
    • The diagnostic evaluation must include, at a minimum, a medical history, physical examination, pulmonary function testing and a computerized tomography (CT) scan of the chest
    • If patients exhibit another pulmonary disease (such as emphysema or asthma), the primary disease must be ILD
  • Anticipated additional follow up at the Registry center within one year

Exclusion Criteria

  • Diagnosed with
    • Sarcoid
    • Lymphangioleiomyomatosis (LAM)
    • Pulmonary alveolar proteinosis (PAP)
    • Cystic fibrosis (CF)
    • Amyloidosis

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Andrew Limper, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions